
This study aimed to determine whether CHD physiologic stage improved predictive power (to predict all-cause mortality) beyond conventional clinical risk models. Of 5321 patients, 1649 (31%), 1968 (37%), 1224 (23%), and 480 (9%) were in stages A, B, C, and D at baseline. The CHD physiologic stage can potentially be used for risk stratification and to monitor disease progression and response to therapy.
Like
Save
Share